Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. Sintx Technologies, Inc. has a collaboration agreement with CTL Amedica to design and launch spinal implants. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone801-839-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90,000.00
Profitability
Miscellaneous
Employees19
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Sintx Technologies (NASDAQ:SINT) Frequently Asked Questions
What is Sintx Technologies' stock symbol?
Sintx Technologies trades on the NASDAQ under the ticker symbol "SINT."
How were Sintx Technologies' earnings last quarter?
Sintx Technologies (NASDAQ:SINT) posted its quarterly earnings results on Thursday, August, 15th. The company reported ($3.99) EPS for the quarter. The company earned $0.17 million during the quarter. View Sintx Technologies' Earnings History.
When is Sintx Technologies' next earnings date?
What price target have analysts set for SINT?
2 equities research analysts have issued twelve-month target prices for Sintx Technologies' shares. Their predictions range from $3.00 to $3.00. On average, they expect Sintx Technologies' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Price Targets for Sintx Technologies.
What is the consensus analysts' recommendation for Sintx Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sintx Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sintx Technologies.
Has Sintx Technologies been receiving favorable news coverage?
News headlines about SINT stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sintx Technologies earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Sintx Technologies.
Are investors shorting Sintx Technologies?
Sintx Technologies saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 114,700 shares, an increase of 12.9% from the August 15th total of 101,600 shares. Based on an average daily volume of 1,190,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 6.0% of the company's stock are short sold. View Sintx Technologies' Current Options Chain.
Who are some of Sintx Technologies' key competitors?
Some companies that are related to Sintx Technologies include Biostage (BSTG), Co-Diagnostics (CODX), RA Medical Systems (RMED), Restoration Robotics (HAIR), Atossa Genetics (ATOS), Hancock Jaffe Laboratories (HJLI), DarioHealth (DRIO), Lianluo Smart (LLIT), Obalon Therapeutics (OBLN), Dynatronics (DYNT), Valeritas (VLRX), Presbia (LENS), Avinger (AVGR), CELLECT BIOTECH/S (APOP) and Invivo Therapeutics (NVIV).
What other stocks do shareholders of Sintx Technologies own?
Who are Sintx Technologies' key executives?
Sintx Technologies' management team includes the folowing people:
- Dr. B. Sonny Bal, Chairman, Pres, CEO & Principal Financial Officer (Age 57)
- Mr. Bryan J. McEntire, Chief Scientific Officer (Age 67)
- Mr. David O'brien, Chief Operating Officer (Age 54)
How do I buy shares of Sintx Technologies?
Shares of SINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sintx Technologies' stock price today?
One share of SINT stock can currently be purchased for approximately $2.46.
How big of a company is Sintx Technologies?
What is Sintx Technologies' official website?
How can I contact Sintx Technologies?
Sintx Technologies' mailing address is 1885 WEST 2100 SOUTH, SALT LAKE CITY UT, 84119. The company can be reached via phone at 801-839-3500 or via email at [email protected]
MarketBeat Community Rating for Sintx Technologies (NASDAQ SINT)
MarketBeat's community ratings are surveys of what our community members think about Sintx Technologies and other stocks. Vote "Outperform" if you believe SINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
